A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies

NCT05269940 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Hodgkin Lymphoma
Peripheral T Cell Lymphoma
CLL/SLL

Interventions

DRUG: ZX-101A

Sponsor

Nanjing Zenshine Pharmaceuticals